Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keyriched-1: Pembrolizumab in HER2-enriched Early Breast Cancer
NCT03988036Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03988036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988036.